Introduction
============

Leukemia, a common malignant disease of the hematopoietic system ([@B19]), can be classified on the basis of speed of disease progression and cell cytogenetics into four common subtypes: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) ([@B2]). The etiology and mechanisms underlying of leukemogenesis are still unclear, although radiation, smoking, obesity and exposure to chemical carcinogens are considered high risk factors ([@B23]; [@B14]; [@B28]; [@B34]). Nevertheless, only a small proportion of people exposed to these risks develops leukemia, suggesting that hereditary factors may play a critical role in leukemia carcinogenesis ([@B24]; [@B18]).

Decreased efficiency of DNA repair is considered a crucial event in carcinogenesis ([@B17]). Recently, a series of studies revealed that reduced DNA repair, leading to chromosomal aberrations and genomic instability, is a major contributor to the pathogenesis of leukemia ([@B9]; [@B12]). The xeroderma pigmentosum group D (XPD) gene, also known as ERCC2, encodes a 5′--3′ superfamily 2 helicase that plays a key role in unwinding the DNA double helix around damaged DNA during nucleotide excision repair (NER) ([@B22]; [@B8]). Because of the biological significance of XPD, XPD polymorphisms have been extensively studied in different malignant diseases, such as pancreatic ([@B46]), colorectal ([@B33]) and gallbladder ([@B43]) cancers.

Several studies have reported inconsistent results on the relationship between the XPD Lys751Gln polymorphism (SNP IDs: rs13181) and leukemia susceptibility. Some studies showed a clear relationship between XPD Lys751Gln polymorphism and an increased risk of leukemia ([@B20]; [@B15]; [@B41]; [@B4], [@B3]), while others showed a decreased risk of leukemia ([@B35]; [@B11]), and others suggested no association between this polymorphism and leukemia ([@B40]; [@B1]; [@B29]; [@B30]; [@B37]; [@B5]; [@B7]; [@B36]; [@B42]; [@B10]). To evaluate more precisely the potential relationship between XPD Lys751Gln polymorphism and leukemia, we hereby report a meta-analysis using all the available published data.

Materials and Methods {#s1}
=====================

Search Strategies
-----------------

A computerized search of Pubmed, Web of Science, EBSCO, the Cochrane Library and China National Knowledge Infrastructure (CNKI) up to March 2017 was conducted using the following search strategy: ("XPD" or "ERCC2" or "xeroderma pigmentosum group D"), and ("polymorphism" or "variant" or "mutation"), and "Leukemia." The search was restricted to English and Chinese language publications. A manual search of the references in the retrieved articles and relevant reviews was also conducted. A flowchart of information pertaining to identification, screening, eligibility, and the final selected datasets was constructed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines ([@B31]).

Inclusion and Exclusion Criteria
--------------------------------

Studies that investigated the association between XPD Lys751Gln polymorphism and leukemia risk were included. The inclusion criteria were (1) case-control study design; (2) available genotype information of the XPD Lys751Gln polymorphism; (3) evaluation of the XPD gene polymorphism and the risk of leukemia; and (4) the distribution of genotypes among the controls was in agreement with the Hardy--Weinberg equilibrium (HWE). The major criteria for exclusion were: (1) duplication of earlier publications (for studies using the same sample in different publications, only the most complete information was included following careful examination), (2) unpublished papers, dissertations, conference articles and reviews, (3) family-based studies of pedigrees.

Data Extraction
---------------

Data from each eligible study were extracted into Excel, and included the country of origin and ethnicity of each study population, age group (adult or childhood), subtypes of leukemia, genotyping method, numbers of cases and controls, numbers of cases and controls in the XPD Lys751Gln genotypes and results of the HWE test.

Study Quality Assessment
------------------------

The quality of the included studies was assessed by two reviewers in accordance with the Newcastle-Ottawa Scale (NOS) ([@B44]), which is used to assess the quality of observational studies. Discrepancies were reported and settled by a third party. Three major aspects of study quality were scored: (1) selection of the study groups (0 ± 4 points); (2) determination of the exposure of interest in the studies (0 ± 3 points); and (3) the quality of the adjustment for confounding variables (0 ± 2 points). A study could be scored with a maximum of one star for each item numbered within the categories of Selection and Exposure, while at most two stars could be allocated to Comparability. A higher score represents a greater quality of the study methodology. A score equal to or higher than 6 was considered to indicate high study quality.

Data Analysis
-------------

The combined odds ratios (ORs) and 95% confidence interval (CI) were used to evaluate the strength of the association with the risk of leukemia. Pooled ORs were performed for allelic comparison (a vs. A), dominant (aa + Aa vs. AA), recessive (aa vs. Aa + AA) and codominant (aa vs. AA and Aa vs. AA) models ("a" and "A" represents the mutant allele and the wild-type allele, respectively). Heterogeneity among the included studies was assessed using the *I*^2^ statistic. A random-effects model or fixed-effects model was used to calculate the pooled OR in the presence or absence of heterogeneity, respectively. To detect possible sources of heterogeneity and potential differences among subgroups, meta-regression and subgroup analyses were carried out with the stratification of different ethnicities, age groups and subtypes of leukemia. The significance of the pooled OR was determined through a *Z*-test, and *p* \< 0.05 was considered to be statistically significant. Publication bias was investigated using funnel plots and Egger's regression test. We also conducted sensitivity analysis to test the robustness of associations by sequentially omitting each of the included studies one at a time. All the data analysis was performed using STATA software 14.0 (StataCorp, College Station, TX, United States) and Review Manager 5.3 (Cochrane Collaboration, Oxford, United Kingdom).

Results
=======

Literature Search and Study Characteristics
-------------------------------------------

We used several search criteria to include or exclude reported studies on the relationship between XPD polymorphism and leukemia (**Figure [1](#F1){ref-type="fig"}**). A total of 14 studies (2,757 cases and 4,768 controls) concerning XPD Lys751Gln polymorphism were included in the final evaluation (**Table [1](#T1){ref-type="table"}**). A quality assessment of the individual studies showed that the Newcastle-Ottawa scale score ranged from 6 to 8, indicating that the quality of the methodology was generally good (**Table [2](#T2){ref-type="table"}**).

![A flow diagram showing the study selection process for the meta-analysis.](fgene-09-00218-g001){#F1}

###### 

Main characteristics of datasets included for the XPD Lys751Gln polymorphism and leukemia risk.

  Author       Year   Country          Ethnicity    Subtypes       Age group      Genotyping method   Sample size   Genotype (n/frequency)   HWE                                                                          
  ------------ ------ ---------------- ------------ -------------- -------------- ------------------- ------------- ------------------------ ------------ ------------ ----------- ------------ ------------ ------------ --------
  Seedhouse    2002   United Kingdom   Caucasians   AML            Adult          PCR-RFLP            122           73                       44 36.07%    59 48.36%    19 15.57%   30 41.10%    32 43.83%    11 15.07%    0.6195
  Allan        2004   United Kingdom   Caucasians   AML            Adult          PCR-RFLP            474           696                      180 37.97%   216 45.57%   78 16.46%   293 42.10%   299 42.96%   104 14.94%   0.0597
  Matullo      2006   European         Caucasians   Unclassified   Adult          TaqMan              169           1094                     70 41.42%    79 46.75%    20 11.83%   397 36.29%   504 46.07%   193 17.64%   0.1330
  Mehta        2006   United States    Caucasians   AML            Child          TaqMan              313           432                      116 37.06%   142 45.37%   55 17.57%   183 42.36%   194 44.91%   55 12.73%    0.7521
                                       African      AML            Child          TaqMan              38            146                      20 52.63%    18 47.37%    0 0%        87 59.59%    52 35.62%    7 4.79%      1.0000
  Pakakasama   2007   Thailand         Asia         ALL            Child          PCR-RFLP            108           317                      87 80.56%    19 17.59%    2 1.85%     260 82.02%   56 17.67%    1 0.31%      0.4932
  Batar        2009   Turkish          Caucasians   ALL            Child          PCR-RFLP            70            75                       26 37.14%    33 47.14%    11 15.72%   27 36.00%    35 46.67%    13 17.33%    0.8119
  Ganster      2009   Austria          Caucasians   CLL            Adult          PCR-RFLP            444           444                      157 35.36%   222 50.00%   65 14.64%   186 41.89%   194 43.69%   64 14.42%    0.2589
  Canalle      2011   Brazil           Caucasians   ALL            Child          PCR-RFLP            162           223                      72 44.44%    78 48.15%    12 7.41%    105 47.09%   101 45.29%   17 7.62%     0.3415
                                       African      ALL            Child          PCR-RFLP            27            138                      16 59.26%    9 33.33%     2 7.41%     91 65.94%    40 28.99%    7 5.07%      0.4134
  Ozcan        2011   Turkish          Caucasians   AML            Adult          PCR-RFLP            35            100                      18 51.43%    16 45.71%    1 2.86%     41 41.00%    41 41.00%    18 18.00%    0.2049
                                                    ALL            Adult          PCR-RFLP            10            100                      4 40.00%     4 40.00%     2 20.00%    41 41.00%    41 41.00%    18 18.00%    
  Shi JY       2011   China            Asia         AML            Adult          MALDI-TOF MS        303           554                      243 80.20%   58 19.14%    2 0.66%     480 86.64%   70 12.64%    4 0.72%      0.3373
  Sorour A     2013   Egypt            Caucasians   AML            Adult          PCR-RFLP            90            60                       33 36.67%    45 50.00%    12 13.33%   27 45.00%    30 50.00%    3 5.00%      0.2197
  Banescu C    2014   Romania          Caucasians   CML            Adult          PCR-RFLP            156           180                      51 32.69%    77 49.36%    28 17.95%   82 45.56%    79 43.89%    19 10.55%    1.0000
  Douzi K      2015   Tunisia          Caucasians   ALL            No age limit   PCR-RFLP            85            206                      33 38.82%    43 50.59%    9 10.59%    92 44.66%    93 45.15%    21 10.19%    0.8742
                                                    AML                           PCR-RFLP            34            206                      21 61.77%    11 32.35%    2 5.88%     92 44.66%    93 45.15%    21 10.19%    
                                                    CML                           PCR-RFLP            87            206                      40 45.98%    46 52.87%    1 1.15%     92 44.66%    93 45.15%    21 10.19%    
  Dincer Y     2015   Turkish          Caucasians   ALL            Child          PCR-RFLP            30            30                       11 36.67%    12 40.00%    7 23.33%    9 30.00%     17 56.67%    4 13.33%     0.4721

AML, Acute myeloid leukemia; ALL, acute lymphoid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia. PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; MALDI-TOF MS, matrix assisted laser desorption/ionization time-of-flight mass spectrometry. HWE P-value in the control group, P \> 0.05 indicates that the participants in the control group met the HWE.

###### 

Quality assessment analysis.

  Number   Author         Selection   Exposure   Comparability   Total score
  -------- -------------- ----------- ---------- --------------- -------------
  1        Seedhouse C    4           2          2               8
  2        Allan JM       3           2          1               6
  3        Matullo G      4           2          1               7
  4        Mehta PA       3           2          1               6
  5        Pakakasama S   3           2          1               6
  6        Batar B        4           2          2               8
  7        Ganster C      4           2          2               8
  8        Canalle R      4           2          1               7
  9        Ozcan Ali      4           2          1               7
  10       Shi JY         3           2          1               6
  11       Sorour A       4           2          1               7
  12       Banescu C      4           2          2               8
  13       Douzi K        3           2          2               7
  14       Dincer Y       4           2          2               8

Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia
-----------------------------------------------------------------------

Since significant heterogeneity was identified in recessive, homozygote and alleles models, a random-effects model was used. The other genetic models were analyzed using a fixed-effects model. Overall, a significant increase in leukemia risk was identified in dominant (Gln/Gln + Lys/Gln vs. Lys/Lys: *I*^2^ = 24%, *P* \< 0.001, **Figure [2](#F2){ref-type="fig"}**) and heterozygote models (Lys/Gln vs. Lys/Lys: *I*^2^ = 0%, *P* \< 0.001, **Figure [3](#F3){ref-type="fig"}**). No significant association was found in recessive (Gln/Gln vs. Lys/Gln + Lys/Lys: *I*^2^ = 43%, *P* = 0.560, **Figure [4](#F4){ref-type="fig"}**) and homozygote (Gln/Gln vs. Lys/Lys: *I*^2^ = 51%, *P* = 0.29, **Figure [5](#F5){ref-type="fig"}**) models. In addition, the allele model showed a borderline significant increase in leukemia risk (Gln vs. Lys: *I*^2^ = 50%, *P* = 0.05, **Figure [6](#F6){ref-type="fig"}**). Moderate heterogeneity (*I*^2^: 43%--51%) was found in the no-association model group. To explore the source of this heterogeneity, a meta-regression analysis was conducted. The results revealed that the heterogeneity was not associated with ethnicity, age, clinical subtype or detection method (*p* ≥ 0.05 in all genetic models). We further explored the source of heterogeneity by removing one study each time. The results showed that [@B29] was one of the central sources of the heterogeneity (its inclusion increased heterogeneity by 12%--24%). No publication bias was found in any of the models. Sensitivity analysis suggested that with exception of the allele model, the results were stable and reliable.

![Comparison of XPD Lys751Gln for overall data in dominant model (Gln/Gln + Lys/Gln vs. Lys/Lys). **(A)** Forest plot, **(B)** funnel plot, **(C)** sensitivity analysis.](fgene-09-00218-g002){#F2}

![Comparison of XPD Lys751Gln for overall data in heterozygote model (Lys/Gln vs. Lys/Lys). **(A)** Forest plot, **(B)** funnel plot, **(C)** sensitivity analysis.](fgene-09-00218-g003){#F3}

![Comparison of XPD Lys751Gln for overall data in recessive model (Gln/Gln vs. Lys/Gln + Lys/Lys). **(A)** Forest plot, **(B)** funnel plot, **(C)** sensitivity analysis.](fgene-09-00218-g004){#F4}

![Comparison of XPD Lys751Gln for overall data in homozygote model (Gln/Gln vs. Lys/Lys). **(A)** Forest plot, **(B)** funnel plot, **(C)** sensitivity analysis.](fgene-09-00218-g005){#F5}

![Comparison of XPD Lys751Gln for overall data in allele model (Gln vs. Lys). **(A)** Forest plot, **(B)** funnel plot, **(C)** sensitivity analysis.](fgene-09-00218-g006){#F6}

Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia by Ethnicity
------------------------------------------------------------------------------------

In Caucasian populations, a significant increase in leukemia risk was found in the heterozygote model (Lys/Gln vs. Lys/Lys: *I*^2^ = 0%, *P* = 0.02) and dominant models (Gln/Gln + Lys/Gln vs. Lys/Lys: *I*^2^ = 14%, *P* = 0.02). No significant association was found in recessive (Gln/Gln vs. Lys/Gln + Lys/Lys: *I*^2^ = 44%, *P* = 0.75), homozygote (Gln/Gln vs. Lys/Lys: *I*^2^ = 55%, *P* = 0.32) and allele models (Gln vs. Lys: *I*^2^ = 47%, *P* = 0.24) (**Table [3](#T3){ref-type="table"}**). In African and Asian populations, the subgroup analysis was unreliable as only two studies were available.

###### 

Summary of pooled OR in different ethnicities.

  Genetic model                Age group    Pooled OR (95% CI)    Heterogeneity   Test for overall effect   Statistical model          
  ---------------------------- ------------ --------------------- --------------- ------------------------- ------------------- ------ ----------------------
  Gln vs. Lys                  Caucasians   1.08 \[0.95--1.21\]   0.04            47%                       1.18                0.24   Random-effects model
                               African      1.16 \[0.74--1.82\]   0.66            0%                        0.63                0.53   Fixed-effects model
                               Asian        1.39 \[1.05--1.86\]   0.45            0%                        2.26                0.02   Fixed-effects model
  GlnGln vs. LysLys            Caucasians   1.16 \[0.87--1.56\]   0.01            55%                       1.00                0.32   Random-effects model
                               African      0.85 \[0.21--3.38\]   0.29            12%                       0.23                0.82   Fixed-effects model
                               Asian        1.77 \[0.48--6.52\]   0.23            30%                       0.86                0.39   Fixed-effects model
  LysGln vs. LysLys            Caucasians   1.15 \[1.02--1.30\]   0.77            0%                        2.34                0.02   Fixed-effects model
                               African      1.41 \[0.81--2.48\]   0.78            0%                        1.20                0.23   Fixed-effects model
                               Asian        1.35 \[0.86--2.14\]   0.17            46%                       1.30                0.19   Random-effects model
  GlnGln + LysGln vs. LysLys   Caucasians   1.15 \[1.02--1.28\]   0.31            14%                       2.39                0.02   Fixed-effects model
                               African      1.33 \[0.77--2.30\]   1.00            0%                        1.02                0.31   Fixed-effects model
                               Asian        1.42 \[1.04--1.94\]   0.27            17%                       2.24                0.03   Fixed-effects model
  GlnGln vs. LysGln + LysLys   Caucasians   1.04 \[0.81--1.33\]   0.05            44%                       0.32                0.75   Random-effects model
                               African      0.75 \[0.19--2.93\]   0.26            22%                       0.41                0.68   Fixed-effects model
                               Asian        1.67 \[0.46--6.14\]   0.21            36%                       0.78                0.44   Fixed-effects model

Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia by Age
------------------------------------------------------------------------------

In a subgroup analysis by age group, one study was excluded as it lacked data on patients' age ([@B11]). Significant associations were consistently found in some genetic models of the adult group (GlnGln + LysGln vs. LysLys: *I*^2^ = 46.0%, *P* = 0.04; LysGln vs. LysLys: *I*^2^ = 9%, *P* = 0.002), and in almost all models of the childhmodels of the childhood group (Gln vs. Lys: *I*^2^ = 0%, *P* = 0.003; GlnGln + LysGln vs. LysLys: *I*^2^ = 0%, *P* = 0.01; GlnGln vs. LysGln + LysLys: *I*^2^ = 0%, *P* = 0.03; GlnGln vs. LysLys: *I*^2^ = 0%, *P* = 0.009; LysGln vs. LysLys: *I*^2^ = 0%, *P* = 0.04). Moderate to higher heterogeneity (*I*^2^: 46%--65%) was found in the no-association models of the adult group (**Table [4](#T4){ref-type="table"}**).

###### 

Summary of pooled OR in different age groups.

  Genetic model                Age group   Pooled OR (95% CI)    Heterogeneity   Test for overall effect   Statistical model           
  ---------------------------- ----------- --------------------- --------------- ------------------------- ------------------- ------- ----------------------
  Gln vs. Lys                  Adult       1.13 \[0.95--1.35\]   0.006           65%                       1.37                0.17    Random-effects model
                               Childhood   1.24 \[1.08--1.43\]   0.74            0%                        2.97                0.003   Fixed-effects model
  GlnGln vs. LysLys            Adult       1.13 \[0.77--1.66\]   0.02            58%                       0.64                0.52    Random-effects model
                               Childhood   1.54 \[1.11--2.13\]   0.54            0%                        1.08                0.28    Fixed-effects model
  LysGln vs. LysLys            Adult       1.24 \[1.08--1.42\]   0.36            9%                        3.06                0.002   Fixed-effects model
                               Childhood   1.21 \[1.01--1.45\]   0.77            0%                        2.05                0.04    Fixed-effects model
  GlnGln+LysGln vs. LysLys     Adult       1.22 \[1.01--1.48\]   0.07            46%                       2.04                0.04    Random-effects model
                               Childhood   1.28 \[1.06--1.54\]   0.65            0%                        2.57                0.01    Fixed-effects model
  GlnGln vs. LysGln + LysLys   Adult       1.03 \[0.76--1.41\]   0.07            47%                       0.19                0.85    Random-effects model
                               Childhood   1.40 \[1.04--1.90\]   0.51            0%                        2.19                0.03    Fixed-effects model

Association Between the XPD Lys751Gln Polymorphism and Risk of Leukemia by Subtype
----------------------------------------------------------------------------------

In a subgroup analysis by leukemia subtypes, one study was excluded as it lacked such data ([@B29]). Significant associations were found in almost all genetic models of acute leukemia (Gln vs. Lys: *I*^2^ = 12%, *P* ≤ 0.001; GlnGln + LysGln vs. LysLys: *I*^2^ = 0%, *P* ≤ 0.001; GlnGln vs. LysLys: *I*^2^ = 14%, *P* = 0.02; LysGln vs. LysLys: *I*^2^ = 0%, *P* = 0.003), and in some models of chronic disease (GlnGln + LysGln vs. LysLys: *I*^2^ = 34%, *P* = 0.009; LysGln vs. LysLys: *I*^2^ = 0%, *P* ≤ 0.001) (**Table [5](#T5){ref-type="table"}**).

###### 

Summary of pooled OR in different leukemia subtype.

  Genetic model                Subtype   Pooled OR (95% CI)    Heterogeneity   Test for overall effect   Statistical model            
  ---------------------------- --------- --------------------- --------------- ------------------------- ------------------- -------- ----------------------
  Gln vs. Lys                  Acute     1.17 \[1.07--1.29\]   0.33            12%                       3.37                0.0007   Fixed-effects model
                               Chronic   1.14 \[0.83--1.57\]   0.03            72%                       0.80                0.42     Random-effects model
  GlnGln vs. LysLys            Acute     1.29 \[1.04--1.59\]   0.32            14%                       2.35                0.02     Fixed-effects model
                               Chronic   1.08 \[0.40--2.88\]   0.01            78%                       0.15                0.88     Random-effects model
  LysGln vs. LysLys            Acute     1.22 \[1.07--1.39\]   0.76            0%                        2.99                0.003    Fixed-effects model
                               Chronic   1.36 \[1.09--1.69\]   0.67            0%                        2.70                0.007    Fixed-effects model
  GlnGln + LysGln vs. LysLys   Acute     1.24 \[1.09--1.40\]   0.63            0%                        3.38                0.0007   Fixed-effects model
                               Chronic   1.32 \[1.07--1.63\]   0.22            34%                       2.60                0.009    Fixed-effects model
  GlnGln vs. LysGln + LysLys   Acute     1.19 \[0.98--1.45\]   0.35            10%                       1.72                0.09     Fixed-effects model
                               Chronic   0.94 \[0.39--2.28\]   0.02            76%                       0.13                0.90     Random-effects model

Discussion
==========

The NER pathway is a highly conserved DNA repair mechanism that removes bulky intra-strand adducts created by agents such as UV radiation and certain chemicals, including several commonly used chemotherapy agents ([@B39]). Genetic polymorphism in DNA repair genes may cause variation in DNA repair capacity, which in turn can lead to cumulative genotoxic damage and increased susceptibility to cancer ([@B11]). As an important component of NER, XPD is an evolutionarily conserved ATP-dependent DNA helicase that plays an essential role in DNA repair ([@B21]). Several studies have suggested that individuals with polymorphisms in XPD or other NER pathway genes may have an increased risk of cancer ([@B38]; [@B16]). Moreover, several molecular epidemiological studies have found an association between XPD polymorphism and leukemia risk in diverse populations. However, the results are inconsistent and even contradictory. We therefore conducted a meta-analysis to globally evaluate the potential relationship between XPD polymorphism and leukemia.

Our results indicate that XPD Lys751Gln polymorphism significantly increases the overall leukemia risk in dominant and heterozygote models, but not in an allele model or homozygote model. The results suggest that heterozygous mutations but not homozygote mutations of XPD (Lys/Gln) may increase genetic susceptibility to leukemia. This may be the result of a higher rate of heterozygous versus homozygous mutations (the ratio between heterozygous and homozygous mutations is 2.27 ∼ 56 in the control and 1.71 ∼ 29 in leukemia). A subgroup analysis by ethnicity showed the same result in a Caucasian population. The exact mechanism underlying the association between the susceptibility to different tumors and XPD Lys751Gln polymorphism is currently unknown. XPD is a 5′--3′ superfamily 2 DNA helicase that opens damaged DNA for bulky lesion repair in NER. The interaction of the C-terminal domain of XPD with the p44 helicase activator protein is critical for both helicase activity and the stability of the Transcription Factor II H (TFIIH) complex, which is essential for RNA polymerase II-mediated transcription initiation and the NER ([@B26]). The XPD C-terminal Lys751Gln polymorphism may alter the structure of the C-terminal domain, there by blocking critical interaction with p44 and creating a destructive TFIIH conformation, which subsequently reduces DNA repair activity ([@B27]; [@B13]; [@B32]). Furthermore, by stratifying the data by age and disease subtype, we found that XPD Lys751Gln polymorphism significantly increased leukemia risk in almost all models of childhood and acute disease. The occurrence and development of leukemia appeared to be regulated by genetic and environmental factors. In children with acute leukemia, malignancy manifests with a short latency period, and therefore there is not enough exposure time to allow the initiation of a long carcinogenic process. Unlike children, adults usually develop cancer because of the cumulative effect of environmental exposure during their life ([@B6]). Therefore, we speculate that genetic polymorphism is more important for childhood and acute leukemia.

Compared with previous reports ([@B25]; [@B45]), the present study has the following advantages: (1) it analyzed the association between XPD Lys751Gln polymorphism and both acute and chronic leukemia; (2) a total of 14 studies (2,757 cases and 4,768 controls) were included in this analysis, there by increasing the statistical power of the analysis. (3) Strict literature inclusion and exclusion criteria were enforced, the Ozdemir's study was excluded from our analysis because of a lack of discerning information between ALL and Burkitt lymphoma patients. However, our research also has some limitations: (1) the number of original studies included in the meta-analysis is relatively small, especially in the subgroup analysis. Future studies on ethnicity, age and subtype of leukemia are needed to further corroborate our findings. (2) Heterogeneity, which can greatly affect the conclusions of meta-analyses, was high in some models. Our results showed that moderate or higher heterogeneity was found in some models, which showed no association with leukemia risk. [@B29] was a major source of this heterogeneity, probably to because of the significant differences in the number of cases and controls.

Conclusion
==========

Our meta-analysis demonstrates that XPD Lys751Gln polymorphism significantly increases overall leukemia risk in dominant and heterozygote models, and that this polymorphism is significantly associated with almost all genetic models of childhood and acute leukemia.
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